Compare Illinois Tool Works Inc. (ITW) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Repligen Corporation Common Stock — how do they compare? Illinois Tool Works Inc. trades at $271.34 (market cap $75.85B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Illinois Tool Works Inc. is far larger — about 6.8× Repligen Corporation Common Stock's market cap, and Illinois Tool Works Inc. pays a 2.58% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and Repligen Corporation Common Stock for 0 Days on average.
| ITW | RGEN | |
|---|---|---|
Market Cap | $75.85B | $11.14B |
Volume | 960,368 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $299.60 | $194.57 |
52-Week Low | $241.07 | $102.87 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $84.70B | $11.02B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $269.47, up 1.64% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of growth. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but faces headwinds from elevated P/E of 24.12 and bearish technical momentum. The company's disciplined capital allocation and sector diversification provide stability, though automotive and foodservice weaknesses present near-term challenges. Valuation appears full given current growth rates.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
